Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis

Condition(s) studied

Study summary

Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) is the second leading cause in China and is receiving increasing global attention. Research on HTG-AP has been hindered by the heterogeneity and complexity of the disease, as well as the limitations of prior single-center studies with small sample sizes, inadequate collection of clinical data, lack of sustainable follow-up, and insufficient tools for large-scale data collection, analysis, and biomarker testing. To address these unique challenges and leverage the opportunity to gain a deeper understanding of HTG-AP, the China Hypertriglyceridemia Pancreatitis Study Group (CHPSG) was initiated in April 2023 as a multi-center collaboration. By utilizing the advantages of multi-center studies, such as external validity and larger sample sizes, CHPSG aims to investigate the prevalence, clinical characteristics, natural history, and risk factors of HTG-AP in China. The consortium will also explore the differences between HTG-AP and other etiologies of pancreatitis, with an emphasis on systemic and local complications, recurrence, and long-term quality of life. Through its phased approach, CHPSG seeks to develop targeted strategies for the prevention and treatment of HTG-AP, ultimately improving patient outcomes.

Eligibility

Primary outcome measure(s)

• Incidence of organ dysfunction — 1-2 weeks
  Assessment of multi-organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and other complications
• Clinical outcomes — 1-2 weeks
  Hospital length of stay, ICU admission rate, and mortality
• Incidence of recurrent HTG-AP — 1 year
  The recurrence rate within a defined period
• Risk factors for recurrence — 1 year
  Identification of factors such as triglyceride (TG) levels, BMI, diabetes status, medication use, and lifestyle habits.

Trial sites (12)

More Peking Union Medical College Hospital trials in China

Other trials for the same condition